IgA Nephropathy: VRTX/VERA/NVS/Otsuka: RAINIER Asymmetric Risk Into the upcoming 2026 phase III

Ahead of VRTX’s phase III RAINIER readout in IgAN (est. mid 2026), povetacicept is currently being viewed as though it is structurally differentiated on the back of the highest headline uPCR reductions seen. Our report, however, finds that this perceived superiority may not be as differentiated as street expectations, leaving downside risk for the RAINIER readout,  and that competitive pressure is likely to be materially stronger than consensus expects. NVS’s Fabhalta’s FDA approval and oral convenience appear underappreciated, while Otsuka’s FDA-approved Voyxact is inappropriately being view a less effective. We see expectations stretched for VRTX’s povetacicept and VERA’s atacicept, while Fabhalta and Voyxact appear conservatively priced, creating asymmetric positioning ahead of the confirmatory 2026 catalysts.

Our report focuses on the core investment debates driving positioning in IgAN today, addressing questions such as:

• How much of the perceived differentiation is due to povetacicept?

• Is the perceived efficacy gap between leading IgAN programmes robust?

• Is the market overpaying for apparent efficacy leadership that may not translate into durable commercial advantage?

• Where is the true clinical and commercial inflection point in IgAN disease control? uPCR? eGFR? What’s the target?

• Are peak share assumptions reflecting real-world segmentation and step-therapy dynamics in moderate disease?